Micro and Macronutrient Deficiencies and Their Correlation with Menopausal Symptoms
Year: 2026
Type: article
Abstract: INTRODUCTION Menopausal symptoms arise from estrogen deficiency, neuroinflammation, and metabolic changes. Nutrition, particularly macro- and micronutrients, is crucial during perimenopause and menopause, as estrogen decline alters metabolism, nutrient absorption, and utilization. Deficiencies in these nutrients can amplify symptom severity, whereas a good diet may mitigate them. MACRONUTRIENT DEFICIENCIES AND MENOPAUSAL SYMPTOMS Macronutrients – proteins, carbohydrates, and fats – provide structural components essential for hormonal regulation, muscle maintenance, and inflammation control. During menopause, estrogen deficiency promotes sarcopenia (muscle loss), visceral fat accumulation, and insulin resistance, which is worsened by inadequate protein intake.[1,2] ICMR 2024 guidelines highlight only 400 mg calcium intake versus 1200 mg RDA, driving parathyroid hormone (PTH) elevation and metabolic syndrome in 70% of cases. Deficiency of magnesium found in 40%–60% women, amplifies neuroinflammation. Postmenopausal women require higher protein intake (1.0–1.2 g/kg body weight daily) to counteract age-related muscle loss and support bone health. Low protein exacerbates menopausal bone and muscle symptoms by mirroring osteoporosis.[3,4] Postmenopausal women with major depressive disorder in late menopause exhibited lower protein intake, high body mass index, fat mass, and persistent mood swings, although early menopausal women reported more acute VMS despite better protein consumption.[5]Figure 1 association of protein intake with menopausal symptoms.Figure 1: Association of protein intake with menopauseCarbohydrate imbalances, often from high refined sugar intake, are linked to glycemic instability and worsened vasomotor symptoms (VMS) [Figure 2].Figure 2: Association of processed carbohydrates with menopausal symptomsMacronutrient deficiencies promote metabolic dysregulation, with protein deficiency directly correlating to musculoskeletal symptoms and mood instability, and imbalanced fats/carbs exacerbating VMS and sleep issues. MICRONUTRIENT DEFICIENCIES AND MENOPAUSAL SYMPTOMS Micronutrients – vitamins and minerals – act as cofactors in hormone synthesis, antioxidant defense, and neural signaling. Estrogen decline impairs their homeostasis, leading to deficiencies that intensify menopausal symptoms. Vitamin D deficiency low levels disrupt thermoregulation, prolonging VMS episodes. Critical appraisals confirm severe deficiency worsens menopausal symptomatology, falls, and fractures, although supplementation benefits are inconsistent unless combined with calcium.[Figure 3] In estrogen-deficient models, Vitamin D shortfall delays menopause onset but heightens symptom severity, including heart discomfort.[6]Figure 3: Vitamin deficiency and menopausal symptomsMAGNESIUM DEFICIENCY It drives neuroinflammation through reduced intracellular Mg2+, exacerbated by estrogen loss. In ovariectomized mice, it caused pain hypersensitivity, memory deficits, and depression-like behaviors through nuclear factor kappa B (NF-κB) activation and elevated tumor necrosis factor-alpha/interleukin-1 beta. Supplementation with magnesium-L-threonate reversed these, suggesting deficiency underlies chronic pain and cognitive fog in 30%–40% of menopausal women. B vitamins, particularly B6, show inverse associations with VMS; higher intake reduces hot flush odds by 8% per 10 μg/MJ, likely through neurotransmitter modulation. It also contributes to bone health by modulating osteoblast and osteoclast activity and maintaining Vitamin D metabolism.[7,8] Menopause accelerates bone resorption. In estrogen-deficient rats, severe calcium restriction elevated PTH, increased visceral fat, downregulated fat oxidation genes, and boosted insulin resistance – hallmarks of metabolic syndrome in menopause. Human data show postmenopausal hypocalcemia correlates with hypertension and depressive symptoms, underscoring its role in cardiovascular and mood disturbances. Adequate intake (1200 mg/day) with Vitamin D prevents osteoporosis-related pain and fractures.[9,10] COGNITIVE AND MOOD REGULATION Neuroprotective roles of several micronutrients have been documented, pertinent to menopausal mood changes and cognitive decline. B vitamins (B6, B12, folate) are essential for neurotransmitter synthesis and homocysteine regulation; deficiencies are linked to depression and cognitive impairment. Micronutrient shortfalls in vegetables, fruits, and whole foods amplify urogenital, joint, and skin symptoms, whereas deficiencies in C and B vitamins heighten oxidative stress. Phytoestrogens from soy may partially offset these, reducing VMS modestly. CARDIOVASCULAR AND METABOLIC HEALTH Micronutrients impact cardiovascular risk factors and metabolic homeostasis, which become critical concerns postmenopause. Vitamins B6, B12, folic acid, and magnesium regulate homocysteine metabolism, lipid profiles, and blood pressure. Chromium supports glucose metabolism and insulin sensitivity, reducing diabetes risk. Antioxidant vitamins (C, E), zinc, and selenium combat oxidative stress and inflammation, mitigating vascular injury and metabolic syndrome progression. INTERPLAY AND CLINICAL IMPLICATIONS The interplay between macro- and micronutrients is synergistic; protein deficiency impairs Vitamin D activation, whereas low calcium/magnesium intake hinders muscle protein synthesis. Balanced diets rich in Mediterranean patterns – high in vegetables, lean proteins, and omega-3 sources – to alleviate symptoms holistically. Increasing protein and micronutrient-dense foods, improve sleep and mood in 60% of cases, outperforming isolated supplements. EMERGING BIOACTIVE SUBSTANCES IN MENOPAUSAL SYMPTOM MANAGEMENT Beyond optimising macro- and micronutrient status, a growing body of research over the past 7 years has highlighted the potential of various nutraceuticals, botanical extracts, and other bioactive compounds to alleviate menopausal symptoms through mechanisms that include phytoestrogenic activity, anti-inflammatory effects, neurotransmitter modulation, and antioxidant protection. These compounds are increasingly considered candidates for inclusion in personalised, multicomponent nutritional strategies. Notable examples supported by recent clinical and preclinical evidence include: Ashwagandha (Withania somnifera) root extract, which has demonstrated reductions in stress-related VMS and improvements in sleep quality and sexual function in perimenopausal women[11] Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women according to results of a randomized controlled study[12] Alpinia galanga and Citrus bergamia (bergamot) polyphenols, which exhibit vasorelaxant and mood-stabilizing properties Phytoestrogenic herbs such as red clover isoflavones, maca (Lepidium meyenii), dong quai (Angelica sinensis), chasteberry (Vitex agnus-castus), and hops (Humulus lupulus) are effective in reducing hot flush frequency and severity in randomised trials Curcumin, resveratrol, quercetin, and green tea catechins (e.g., epigallocatechin-3-gallate [EGCG]) exhibit strong anti-inflammatory and antioxidant properties that reduce neuroinflammation through NF-κB pathway inhibition and alleviate endothelial dysfunction by lowering ROS and enhancing nitric oxide bioavailability, potentially stabilizing VMS[13-15] Pomegranate ellagitannins and lycopene support cardiovascular and urogenital health through nitric oxide modulation and reduction of oxidative stress Valerian root and lemon balm combinations, as well as kava (Piper methysticum) and licorice (Glycyrrhiza glabra), are noted for anxiolytic and sleep-promoting effects[16] Mineral cofactors such as zinc and iron, which, when deficient, exacerbate fatigue, cognitive complaints, and mood disturbances commonly reported during the menopausal transition. A one-size-fits-all approach is unlikely to be optimal. Personalised combination supplements tailored to each woman’s symptoms, biomarker profile (e.g., Vitamin D or magnesium status, inflammatory markers) are recommended as these enhance efficacy, minimizes adverse effects, and improve long-term adherence compared with generic multivitamin or single-herb preparations. In conclusion, integrating evidence-based bioactive compounds with targeted macro- and micronutrient repletion offers a promising, holistic framework for managing menopausal symptoms. Ongoing and future randomized controlled trials should prioritize multiingredient formulations designed through a personalised lens to establish optimal dosing, synergy, and long-term safety. CONCLUSION Micro- and macronutrient deficiencies significantly correlate with intensified menopausal symptoms, from VMS to osteoporosis. Protein deficiency (<1.0 g/kg/day) accelerate sarcopenia and osteoporosis, whereas calcium, Vitamin D, magnesium, and B6 gaps intensify VMS, pain hypersensitivity, and cognitive fog through disrupted thermoregulation, NF-κB activation, and homocysteine elevation. Human cohort studies confirm that late-postmenopausal women with major depression exhibit macronutrient deficits correlating with higher BMI and persistent mood instability. Emerging nutraceuticals – ashwagandha (300 mg BID), collagen peptides (5 g/day), phytoestrogens (red clover 80 mg), and polyphenol combinations (curcumin/resveratrol/EGCG) – offer synergistic relief through adaptogenic, anti-inflammatory, and phytoestrogenic mechanisms, reducing MRS scores by 20%–47% in randomized controlled trials (RCTs) without hormonal risks For Indian women facing Vitamin D deficiency in 70%–90%, protein deficiency (65%) and metabolic syndrome, nutrition represents a cornerstone of nonpharmacological menopausal care.[17] Adopting nutrient-rich diets during perimenopause can mitigate these, emphasizing prevention.[18] Future RCTs should explore combined interventions for personalized care.
Source: Journal of Mid-life Health
Author: Ruchika Garg
Institution: Sarojini Naidu Medical College
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7127595450